-
Our Mission
To provide novel and effective therapeutic monitoring options for the treatment of Neonatal NAS (Neonatal Abstinence Syndrome) that are individually tailored to patients. This includes both medication and non-medication assisted therapies, and solutions that could potentially address the OUD epidemic crisis.
-
Our Vision
To use a smart integrated platform with the latest transformative technology to address the unmet needs of NAS.
-
Our Values
To innovate, improve the quality of patient services, and provide solutions to the patients while honoring our financial responsibilities to our shareholders.
More about Rekovar
We use cutting edge technology to address the unmet needs from NAS babies. We automate the assessment of neonates and medication dosage delivery.
We give back to our local comminutes, hire from local universities, and provide a healthy work environment where students learn and grow.
Here at Rekovar, our goal is to reduce mortality, protect more infants, improve their quality of life, and provide consistent healthcare.
Who We Are
Founded in late 2018, Rekovar is a women-owned startup company funded by NIH - National Institute on Drug Abuse supporting scientific research on drug use and addiction.
We are currently working on a product revolutionizing neonatal care with our AI-focused, patent-pending wearable technology. Our innovative device provides real-time insights into the vital signs and symptoms of NAS, enabling healthcare professionals to deliver personalized care and intervention.
Join us as we redefine standards in healthcare and create a brighter future for babies.
